The Rheumatology Podcast cover art

All Episodes

The Rheumatology Podcast — 137 episodes

#
Title
1

Dr Vanessa Smith on simple capillaroscopic definitions to describe capillary morpholog

2

Air pollution and RA flares

3

Precision medicine in autoimmune diseases

4

Trainee Publishing Programme 2021: Aimie Patience

5

Chetan Mukhtyar on the long-term use of tocilizumab in giant cell arteritis

6

Prof Raphaèle Seror on smoking status and the risk of incident RA

7

Wolfgang Schmidt on the use of ultrasound in diagnosing and managing giant cell arteritis (GCA)

8

RA patient access to DMARDs in Norway

9

Results from the NEIAA Short Report on Ethnicity

10

Dr David Fajgenbaum on cytokine storm syndromes

11

Rheumatology Podcast - Bernard Lauwerys

12

Dr John Hanly on lupus nephritis

13

BSR myositis guideline: What does this mean for patients?

14

BSR myositis guideline: Clinical updates

15

Improving outcomes for hospitalised gout patients

16

Safety and clinical activity of atacicept in SLE

17

BSR guidelines on axial spondyloarthritis

18

Treating IgG4-related disease with rituximab

19

Prof Jon Giles - Muscle mass relative to fat mass with physical function in RA

20

Dr Steven Zhao on comorbidities and disease activity in axSpA

21

De novo lupus nephritis and belimumab

22

Trainee Publishing Programme 2021: Dr Sreejitha Sreevilasan

23

Comparing IgG and IgG + IgM anti-dsDNA assays

24

Biomarkers for paediatric cytokine storm syndromes

25

Prof. Frances Williams on chronic widespread pain and the gut microbiome

26

Dr. Iona Thorne on reproductive health in women with rheumatic disease

27

Julie Paik on tofacitinib monotherapy in the treatment of calcinosis in refractory DM

28

Dr. Sara Booth on employment practice and SLE

29

Dr Chris Rooney on the gut microbiome and rheumatoid arthritis

30

Dr Gouri Koduri on patient perceptions of comorbidities

31

Mark McClure on prediction models in ANCA-associated vasculitis

32

Learning and lessons from the EUVAS case report supplement

33

Dr Peter Grayson on VEXAS syndrome

34

Prof. Paul Emery on COVID-19 vaccination and antirheumatic therapy

35

Comparing and contrasting RA ILD and IPF

36

NEIAA: Predicting disease activity in early inflammatory arthritis

37

Dr Alfred Kim on non-adherence and physician-patient interactions in SLE

38

Prof. Elaine Yacyshyn and Dr Whitney Hung on checkpoint inhibitor-induced GPA

39

Foot and ankle care in people with rheumatoid arthritis

40

Dr Ioannis Parodis on BMI and health-related quality of life in SLE

41

Dr Josep Ribalta on the atherogenic effect of LDL on endothelial cells

42

Dr Elizabeth Price on the upcoming BSR Sjögren’s syndrome guideline

43

Dr Matthew Basiaga on classifying and diagnosing paediatric Sjögren’s syndrome

44

Retrospectively reviewing polymyositis diagnoses in a large single-centre cohort

45

Dr Rosemary Hollick on telephone-based CBT in axSpA

46

Dr Fiona Pearce on the risk of death among RAIRD patients during the COVID-19 pandemic

47

Dr Filipa Farinha on membranous and proliferative lupus nephritis

48

Dr Neil Basu on the effect of anti-TNF therapy on fatigue in ax-SpA

49

Dr Carlos Fernández-Díaz on abatacept in RA ILD

50

Dr William Tillett and Dr Laura Coates on the upcoming BSR PsA guideline

51

Dr Deva Situnayake on Behçet's disease and the THIN database

52

Dr Lewis Carpenter on clinical markers and patient-reported outcomes in early RA

53

Md Yuzaiful Md Yusof on infection and drug survival from the use of biological therapies in RA-associated bronchiectasis

54

Dr Philip Hamann on RA trajectories, real world data and AI

55

Dr Mrinalini Dey and Dr Kathrine Grøn discuss infection risk in RA

56

Dr Marwan Bukhari and Dr Kanta Kumar discuss COVID-19 and ethnicity

57

Dr Steven Zhao and Dr Cristina Maglio discuss bariatric surgery and rheumatoid arthritis

58

Dr Chris Wincup and Dr Elena Nikiphorou discuss methotrexate and interstitial lung disease in RA

59

Dr Marwan Bukhari talks to Prof Danieli Andrade about pregnancy outcomes in mixed connective tissue disease

60

Dr Marwan Bukhari talks to Dr Hannah Jethwa about transforming rheumatology services post-COVID-19

61

Dr Marwan Bukhari talks to Dr Eline Houben about cardiovascular risk factors in ANCA-associated vasculitis

62

Dr Marwan Bukhari talks to Dr Philipp Bosch about measuring disease activity in PsA using ultrasound

63

Dr Marwan Bukhari discusses PET/CT scans in relapsing polychondritis with Dr Aman Sharma

64

Dr Chris Wincup talks to Dr Giacomo De Luca about the use of apremilast in Behçet’s disease.

65

Dr Marwan Bukhari talks to Professor John McBeth on sensitisation fatigue

66

Dr Marwan Bukhari talks to Dr Helena Marzo-Ortega on the use of MRI in the diagnosis of axSpA

67

Dr Marwan Bukhari talks to Dr Harsha Gunawardena

68

Dr Abhishek Abhishek on his recent paper on the Gout Activity Score

69

Dr Carly Janssen on care for acute gout flares and measures in clinical trials

70

Prof Kimme Hyrich on her work on Rheumatology’s real-world data supplement

71

Dr Matthew J. Koster on the diagnosis, monitoring and management of large-vessel GCA

72

Dr Laura Cappelli on shared epitope alleles and immune checkpoint inhibitor-induced inflammatory arthritis

73

Dr Sujith Subesinghe on biologic prescribing decisions following serious infection in RA patients

74

Dr Chris Holroyd on the updated BSR biologic DMARD safety guidelines in inflammatory arthritis

75

Marwan Bukhari and Associate Editor, Xenofon Baraliakos, on what he looks for in a paper

76

Dr Andrew Filer on the role of ultrasound-defined tenosynovitis

77

Dr Susan Goodman on management of perioperative TNFα inhibitors

78

Dr Faith Matcham on the relationship between depression and biologic treatment response in rheumatoid arthritis

79

Dr Edward Roddy on the recently conducted gout audit

80

Prof Yoshiya Tanaka on strategic treatment of psoriatic arthritis patients

81

Prof. Jacques Morel on risk factors of serious infections in patients with RA treated with tocilizumab

82

Dr Karl Gaffney on the BSR and BHPR guideline for the treatment of axial spondyloarthritis

83

Dr Helena Andersson on long-term experience with rituximab

84

Colour duplex sonography in the routine care of GCA

85

Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus

86

BSR guideline for the management of systemic lupus erythematosus in adults

87

BSR and BHPR guideline for the prescription and monitoring of non-biologic DMARDS

88

Twitter, #alternativefacts, careless whispers and Rheumatology

89

BSR Guideline for the Management of Gout

90

Management of Sjögren's Syndrome

91

Rheumatology Podcast - Lars Erik Kristensen

92

Rheumatology Podcast - Astrid van Tubergen

93

Rheumatology podcast episode 44

94

Guidance for the treatment of systemic sclerosis – July 2016

95

Guidance on prescribing drugs in pregnancy and breastfeeding – May 2016

96

Relapse and treatment outcomes in biopsy-proven giant cell arteritis - March 2016

97

Effect of allopurinol on all-cause mortality in adults with incident gout: propensity score–matched landmark analysis - February 2016

98

Fast-track ultrasound clinic for early diagnosis of GCA - December 2015

99

Vasculitis associated with RA - July 2014

100

Change at the top - February 2014

101

Treatment for antiphospholipid antibodies – Jan 2014

102

The evolution of RA treatment: Will we find the cure? – Jan 2014

103

A new kidney-specific diagnostic marker to assess disease activity in lupus nephritis - Dec 2013

104

Managing patients with early RA - July 2013

105

Systemic sclerosis: subsets and diagnosis - July 2013

106

New molecules for the treatment of rheumatoid arthritis - July 2013

107

Epigenetics and autoimmune disease - July 2013

108

Frequency of anti-infliximab antibodies: patients with RA in routine care – (May 2013)

109

Uric acid-lowering therapy: treatment of gout – (April 2013)

110

Role of patients in the management of RA – (January 2013)

111

Cardiovascular risk in ankylosing spondylitis – (December 2012)

112

MRI of joints in children – (November 2012)

113

Keeping pace with changes in vasculitis – (August 2012)

114

Physical activity in RA patients – (June 2012)

115

Evidence for use of complementary medicine in RA – (June 2012)

116

Ultrasound guided steroid injections in children – (May 2012)

117

Psoriatic arthritis and a placebo controlled RCT- (April 2012)

118

ANCA-associated vasculitis- (March 2012)

119

BSR and BHPR guidelines on the use of rituximab – (Feb 2012)

120

Inflammatory myopathies - (June 2011)

121

Early Rheumatoid Arthritis treatment strategies - (June 2011)

122

Patient perceptions - (June 2011)

123

Cohorts in rheumatoid arthritis - (May 2011)

124

50th Anniversary: A perspective on the past - (March 2011)

125

Registries - (January 2011)

126

Is rheumatoid arthritis a genetically distinct subset? - (September 2010)

127

Factors predictive of thrombotic events in SLE patients - (August 2010)

128

Spondyloarthropathies: Ankylosing spondylitis with and without concomitant psoriasis - (July 2010)

129

Increase in ferritin levels and interstitial lung disease in dermatomyositis - (May 2010)

130

Cost of using TNF-alpha inhibitors - (April 2010)

131

Cardiovascular disease and rheumatoid arthritis: what is the link? - (March 2010)

132

Hypermobility in children - (February 2010)

133

The role of biomarkers in the treatment of rheumatoid arthritis - (January 2010)

134

Rheumatoid arthritis in elderly patients - (December 2009)

135

Active rheumatoid arthritis - (November 2009)

136

Management of Systemic Sclerosis - (July 2009)

137

Antiphospholipid antibody syndrome - (June 2009)